Treatment of vascular anomalies
AssigneeGillies Mcindoe Research Institute
InventorsSwee Thong Tan, Paul Frank Davis, Tinte Itinteang
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel approach to the diagnosis, treatment and management of vascular anomalies by providing compositions and methods for the identification and specific targeting of the embryonic stem cell populations associated with vascular anomalies, by modulation of the Renin-Angiotensin System expressed by the stem cells.
Claims12
A method for preventing, treating, or managing vascular anomalies in a patient in need thereof, the method comprising administering a therapeutic agent(s) to the patient in an amount sufficient to selectively eradicate, or inhibit the growth, proliferation and/or differentiation of embryonic stem cells associated with vascular anomalies, wherein the embryonic stem cells are characterized by (i) the expression of one or more embryonic stem cell biomarkers, and (ii) the expression of one or more biomarkers associated with the Renin-Angiotensin System.
A method for preventing, treating, or managing vascular anomalies in a patient in need thereof, the method comprising administering a therapeutic agent to the patient in an amount sufficient to selectively eradicate or inhibit the growth, proliferation and/or differentiation of embryonic stem cells associated with vascular anomalies, wherein the embryonic stem cells are characterized by (i) expression of the embryonic stem cell biomarkers OCT4, SOX2, NANOG and PSTAT3, and (ii) expression of the Renin-Angiotensin System biomarkers Renin Receptor and Angiotensin Converting Enzyme, and wherein the therapeutic agent in selected from the group consisting of Direct Renin Inhibitors (DRIs), Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blockers (ARBs), Beta-Blockers, Cyclo-oxygenase 2 Inhibitors, Chymase Inhibitors, Inhibitors of Cathepsin B, Cathepsin D and Cathepsin G, Calcium, Vitamin D, and Calcium Channel Blockers.
-13. (canceled)
A kit for use in the treatment of vascular anomalies, the kit comprising a therapeutic agent sufficient to selectively eradicate, or inhibit the growth, proliferation and/or differentiation of embryonic stem cells associated with vascular anomalies, together with instructions for how to administer a therapeutic dose to the subject.
Dependencies are inferred from the claim text.